Anisodamine combined with lidocaine improves healing of myocardial ischemia reperfusion injury in rats via PI3K/Akt signaling pathway

Author:

Wang Shouyi,Chen Jiahao,Wang Jie,Que Hongbo,Wei Daming,Zhu Yanhao,Liu Qin,Liu Yu,Zhu Chunyan

Abstract

Purpose: To study the effects of anisodamine (Ad) combined with lidocaine (Ldc) on myocardial ischemia-reperfusion injury (MIRI) in rats, and its correlation with PI3K/AKT signaling pathway.Methods: A total of 70 healthy rats were randomly divided into S group, M group, Ad group, Ldc group, Ad + Ldc group, Ad + Ldc + LY group, and LY group. The cardiac hemodynamic indices in each group were determined, and the area of myocardial infarction measured. Serum biochemical indices were also determined. Furthermore, the protein expressions of p-Akt, T-Akt, Bcl-2, and Bax in myocardial cells were determined by Western blotting.Results: Compared with those in M group, Ad group, Ldc group, Ad + Ldc + LY group, and LY group, cardiac hemodynamic indices significantly improved, while the area of myocardial infarction was significantly reduced (p < 0.01). Furthermore, serum malondialdehyde (MDA) concentration but the activities of CK, CK-MB, TNF-α, and IL-6 declined, while the activities of superoxide dismutase (SOD), CAT and GSH-Px rose in Ad + Ldc group (p < 0.01). In Ad + Ldc group, p-Akt, T-Akt, and Bcl-2 increased, while Bax significantly decreased. Through comparison LY294002 significantly inhibited the protective effect of Ad combined with Ldc against MIRI in rats (p < 0.01).Conclusion: Anisodamine combination with lidocaine has a protective effect against MIRI in rats via PI3K/Akt signaling pathway, thus indicating that it is a potential therapeutic strategy for the management of myocardial ischemia-reperfusion.

Publisher

African Journals Online (AJOL)

Subject

Pharmacology (medical),Pharmaceutical Science

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3